Kura's Q3 Revenue Misses by $10M Despite Narrower-Than-Expected Loss
KURA is trading near its 52-week low of $6.75 (8.0% above the low).
Summary
Kura posted a Q3 adjusted loss of 78 cents a share, better than the 82-cent consensus, but revenue of $13.92 million came in far below the $23.88 million analysts expected. The top-line shortfall is the story: the $13.9 million is entirely KOMZIFTI net product revenue, up 53% sequentially from Q2's $9.1 million, so the miss is against a consensus that was not modeling the launch ramp correctly. The company also reported a quarterly net loss of $70.22 million. Shares had already fallen 29.3% this quarter and 27.1% year to date heading into this print, and the stock closed at $7.57. The 10-Q filed tonight confirms $492.1 million in cash plus a new $275.0 million Oberland debt facility and a ziftomenib royalty agreement signed November 9, so funding is not the near-term issue — commercial execution on KOMZIFTI is.
At the time of this announcement, KURA was trading at $7.29 on NASDAQ in the Life Sciences sector, with a market capitalization of approximately $673.4M. The 52-week trading range was $6.75 to $13.90. This news item was assessed with negative market sentiment and an importance score of 7 out of 10. Source: Reuters.